A5041362178- Migraine and Headache Studies
- Trigeminal Neuralgia and Treatments
- Long-Term Effects of COVID-19
- COVID-19 Clinical Research Studies
- Sympathectomy and Hyperhidrosis Treatments
- COVID-19 and Mental Health
- SARS-CoV-2 and COVID-19 Research
- Botulinum Toxin and Related Neurological Disorders
- Neurological Complications and Syndromes
- Multiple Sclerosis Research Studies
- Neuroinflammation and Neurodegeneration Mechanisms
- Cardiovascular Syncope and Autonomic Disorders
- Peripheral Neuropathies and Disorders
- COVID-19 and healthcare impacts
- Psychosomatic Disorders and Their Treatments
- Alzheimer's disease research and treatments
- Body Image and Dysmorphia Studies
- Intensive Care Unit Cognitive Disorders
- Infectious Encephalopathies and Encephalitis
- Ophthalmology and Eye Disorders
- Nicotinic Acetylcholine Receptors Study
- Neuropeptides and Animal Physiology
- Neurological Disorders and Treatments
- Retinal and Optic Conditions
- Cancer Immunotherapy and Biomarkers
Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia
2018-2025
University of Brescia
2019-2024
Brescia University
2023
Ospedale Papa Giovanni XXIII
2020-2021
Ospedale Maggiore
2021
Azienda Socio Sanitaria Territoriale di Cremona
2021
Ospedale di Bolzano
2021
Istituti Ospitalieri di Cremona
2021
Azienda Ospedaliera Ospedale Maggiore
2021
University of Bologna
2020
To report clinical and laboratory characteristics, treatment, outcomes of patients admitted for neurologic diseases with without coronavirus disease 2019 (COVID-19).
Several preclinical and clinical investigations have argued for nervous system involvement in severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. Some sparse case reports described various forms of encephalitis disease 2019 (COVID-19) disease, but very few data focused on presentations, course, response to treatment, outcomes.The SARS-CoV-2 related encephalopaties (ENCOVID) multicenter study included patients with full infectious screening, cerebrospinal fluid (CSF),...
Abstract Background and purpose A rapid response to preventive therapy is of pivotal importance in severely disabled patients with chronic migraine (CM) diverse treatment failures. This prospective, observational, multicenter real‐life study aimed at investigating the effectiveness galcanezumab first 3 months CM 14 Italian headache centers. Methods All consecutive adult diagnosis clinical indication for were considered. We collected patients' baseline characteristics, monthly days,...
Abstract Background and purpose Based on their pharmacological target, two classes of calcitonin‐gene‐related peptide (CGRP) monoclonal antibodies (mAbs) have been identified: against the CGRP ligand—galcanezumab, fremanezumab, eptinezumab—and receptor (CGRP‐R), erenumab. The aim present study was to compare anti‐CGRP versus anti‐CGRP‐R mAbs in patients with high frequency episodic chronic migraine. Methods All monthly treatment an available 6 months’ follow‐up at January 2022 were included....
Background: Albeit numerous studies have investigated clinical, radiological and biochemical response predictors, the clinical profile of those patients who might benefit from OnabotulinumtoxinA is still missing. Aim present study was to identify potential predictors among several characteristics confirm efficacy safety in chronic migraine (CM) prevention. Methods: The conducted at Headache Centre – Neurology Clinic Spedali Civili Hospital Brescia. Eighty-four consecutive CM were enrolled,...
Neurodegeneration plays a major role in determining disability multiple sclerosis (MS) patients. Hence, there is increasing need to identify reliable biomarkers, which could serve as prognostic measure of disease progression.To assess whether cerebrospinal fluid (CSF) tau and β-amyloid (Aβ) levels were altered newly diagnosed MS patients correlated with disability. Moreover, we investigated these CSF biomarkers associate macroscopic brain tissue damage measures.CSF Aβ determined by...
The aim of the present study was to assess migraine outcome, in particular disability, chronic (CM) and high frequency episodic (HFEM) patients treatment with galcanezumab.The conducted at Headache Centre Spedali Civili Brescia. Patients were treated galcanezumab 120 mg monthly. Clinical demographical information collected baseline (T0). Data about analgesics consumption disability (MIDAS HIT-6 scores) quarterly.Fifty-four consecutive enrolled. Thirty-seven had a diagnosis CM, 17 HFEM....
This study aimed to assess the prevalence and clinical characteristics of headaches, in particular secondary headaches.This observational was performed at ASST Spedali Civili Brescia, Italy. Visits Emergency Department (ED) subsequent hospitalizations regarding a new or worsening headache 16 days following administration COVID-19 vaccine between January 2021 2022 were recorded compared with those 2019-January 2020.The ratio ED admissions due headaches total significantly higher 2019 (4.84%...
To assess migraine outcome after 12-month treatment with erenumab and compare patients who underwent 3-month discontinuation following the first cycle those continued monthly administrations.This is a multicentric observational study in erenumab. After full (T12), could either continue or discontinue for at least 3 months. Patients were assessed months (T15) to decide whether start retreatment. then T16 T18.Thirty consecutive enrolled. Nineteen suspension T12 up T15, whereas 11 prophylaxis....
Aim of the present observational study was to assess impact coronavirus disease 2019 (COVID-19) quarantine on migraine and evaluate potential influencing factors. Previous studies reported mixed results regarding clinical outcome during in patients with migraine. In particular, data from areas strongly affected by COVID-19 pandemic are missing.One hundred seventy patients, previously assessed at Headache Centre-ASST Spedali Civili Brescia, underwent a telephonic interview features clinical,...
Calcitonin gene-related peptide (CGRP) plays a pivotal role in migraine physiology, not only regarding pain but also associated symptoms such as photophobia. The aim of the present study was to assess monoclonal antibodies targeting CGRP efficacy terms headache and frequency disability reducing ictal photophobia.This is retrospective observational study, conducted at Headache Center-ASST Spedali Civili Brescia. All patients monthly treatment with galcanezumab least 6-month follow-up...
Abstract Objective To report the clinical and laboratory characteristics, as well treatment outcomes of patients admitted for neurological diseases with COVID-19 in a Neuro-COVID unit compared to without COVID-19. Methods In this retrospective, single centre cohort study, we included all adult inpatients confirmed COVID-19, who had been discharged or died by April 5, 2020. Demographic, clinical, treatment, data were extracted from medical records. Results 173 whom 56 resulted positive 117...
Abstract Objective Aim of this study was to analyse the impact COVID-19 on clinical and laboratory findings outcome neurological patients consecutively admitted emergency department (ED) a tertiary hub center. Methods All adult ED for manifestations from February 20 th through April 30 2020 at Spedali Civili Brescia entered study. Demographic, clinical, data were extracted medical records compared between with without COVID-19. Results Out 505 evaluated symptoms, 147 (29.1%) tested positive...
The aim of this study is to evaluate the differences in clinical presentations and impact healthcare organization on outcomes neurological COVID-19 patients admitted during first second pandemic waves.In single-center cohort study, we included all with SARS-CoV-2 infection a Neuro-COVID Unit. Demographic, clinical, laboratory data were compared between waves pandemic.Two hundred twenty-three included, whom 112 111 hospitalized waves, respectively. Patients wave younger exhibited pulmonary...
The aim of the present study was to assess erenumab efficacy in migraine disability and intensity throughout first treatment cycle, discontinuation, 6 months re-treatment patients with high-frequency episodic migraine. design retrospective observational. Inclusion criteria were following: diagnosis ongoing 140 mg currently at their second cycle. Data regarding frequency, (MIDAS score), severity attacks (NRS score) collected quarterly. Twenty-five enrolled. At end compared baseline, a...
Keywords CGRP •